JP2015529219A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529219A5 JP2015529219A5 JP2015530559A JP2015530559A JP2015529219A5 JP 2015529219 A5 JP2015529219 A5 JP 2015529219A5 JP 2015530559 A JP2015530559 A JP 2015530559A JP 2015530559 A JP2015530559 A JP 2015530559A JP 2015529219 A5 JP2015529219 A5 JP 2015529219A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- amino acid
- peptide according
- acid sequence
- apc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 31
- 150000001413 amino acids Chemical class 0.000 claims 15
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 11
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 229940024606 amino acid Drugs 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- 210000001808 exosome Anatomy 0.000 claims 3
- 229930182817 methionine Chemical group 0.000 claims 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 2
- 101000837581 Homo sapiens Ubiquitin-conjugating enzyme E2 T Proteins 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical group C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- 102100028705 Ubiquitin-conjugating enzyme E2 T Human genes 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 1
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 102000015636 Oligopeptides Human genes 0.000 claims 1
- 108010038807 Oligopeptides Proteins 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical group OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261699550P | 2012-09-11 | 2012-09-11 | |
| US61/699,550 | 2012-09-11 | ||
| PCT/JP2013/005321 WO2014041784A1 (en) | 2012-09-11 | 2013-09-09 | Ube2t peptides and vaccines containing the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015529219A JP2015529219A (ja) | 2015-10-05 |
| JP2015529219A5 true JP2015529219A5 (OSRAM) | 2016-10-13 |
| JP6283861B2 JP6283861B2 (ja) | 2018-02-28 |
Family
ID=50277926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015530559A Active JP6283861B2 (ja) | 2012-09-11 | 2013-09-09 | Ｕｂｅ２ｔペプチドおよびそれを含むワクチン |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10092634B2 (OSRAM) |
| EP (1) | EP2895600B1 (OSRAM) |
| JP (1) | JP6283861B2 (OSRAM) |
| KR (1) | KR102110873B1 (OSRAM) |
| CN (2) | CN104619833B (OSRAM) |
| AU (1) | AU2013317194B2 (OSRAM) |
| BR (1) | BR112015004349B1 (OSRAM) |
| CA (1) | CA2873155C (OSRAM) |
| DK (1) | DK2895600T3 (OSRAM) |
| ES (1) | ES2784862T3 (OSRAM) |
| IL (1) | IL236690B (OSRAM) |
| MX (1) | MX362912B (OSRAM) |
| PL (1) | PL2895600T3 (OSRAM) |
| RU (1) | RU2663350C2 (OSRAM) |
| SG (2) | SG11201501761SA (OSRAM) |
| TW (1) | TWI632162B (OSRAM) |
| WO (1) | WO2014041784A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017070237A1 (en) | 2015-10-19 | 2017-04-27 | University Of Maryland, Baltimore | Methods for generating engineered human primary blood dendritic cell lines |
| JP6715004B2 (ja) | 2015-12-25 | 2020-07-01 | 宏 半田 | 免疫賦活化剤およびその製造方法 |
| HRP20220605T1 (hr) | 2017-01-25 | 2022-07-08 | Ose Immunotherapeutics | Postupak za proizvodnju stabilne emulzije za isporuku peptida |
| EP3691662A4 (en) * | 2017-10-06 | 2021-05-12 | The University of Chicago | Screening of t lymphocytes for cancer-specific antigens |
| KR102322832B1 (ko) * | 2019-04-22 | 2021-11-12 | 한국과학기술연구원 | 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도 |
| CN113679829B (zh) | 2020-05-18 | 2024-01-02 | 北京繁易纳维科技有限公司 | 一种预防癌症术后复发的肿瘤疫苗及其制备方法和应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| CA2262006A1 (en) | 1996-07-26 | 1998-02-05 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| CN1318447C (zh) | 1998-06-25 | 2007-05-30 | 伊东恭悟 | 得自亲环蛋白b的肿瘤抗原肽 |
| AU762812B2 (en) | 1998-07-14 | 2003-07-03 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| PL202399B1 (pl) | 1998-10-05 | 2009-06-30 | Pharmexa As | Zastosowanie adiuwanta i pierwszego analogu polipeptydowego antygenu związanego z komórką lub co najmniej jednego fragmentu kwasu nukleinowego kodującego epitop CTL pochodzący z antygenu polipeptydowego związanego z komórką lub niepatogennego mikroorganizmu lub wirusa, który niesie fragment kwasu nukleinowego, który koduje i wyraża co najmniej jeden epitop CTL pochodzący z antygenu polipeptydowego związanego z komórką, sposób selekcji immunogennego analogu antygenu polipeptydowego związanego z komórką, sposób wytwarzania komórki wytwarzającej analog an |
| US6468546B1 (en) | 1998-12-17 | 2002-10-22 | Corixa Corporation | Compositions and methods for therapy and diagnosis of ovarian cancer |
| DE60133287T2 (de) * | 2000-07-31 | 2009-03-26 | Green Peptide Co., Ltd., Kurume | Tumorantigen |
| US20070202109A1 (en) | 2003-09-24 | 2007-08-30 | Oncotherapy Science, Inc. | Method Of Diagnosing Breast Cancer |
| EP1668354A2 (en) | 2003-09-24 | 2006-06-14 | Oncotherapy Science, Inc. | Method of diagnosing breast cancer |
| WO2008102906A1 (en) | 2007-02-20 | 2008-08-28 | Oncotherapy Science, Inc. | Hspc-hrpc transition genes |
| TWI596109B (zh) | 2007-02-21 | 2017-08-21 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| TW200908998A (en) | 2007-06-27 | 2009-03-01 | Oncotherapy Science Inc | Compositions and methods of treating cancer |
| EP2340851A4 (en) | 2008-09-18 | 2012-09-26 | Univ Keio | DIAGNOSTIC METHOD AND THERAPEUTIC METHOD FOR CANCER |
| TWI500932B (zh) | 2008-12-05 | 2015-09-21 | Oncotherapy Science Inc | Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗 |
| AU2009332389A1 (en) | 2008-12-24 | 2011-07-14 | Oncotherapy Science, Inc. | C1orf59 peptides and vaccines including the same |
| TW201102081A (en) | 2009-05-11 | 2011-01-16 | Oncotherapy Science Inc | TTK peptides and vaccines including the same |
| TW201216982A (en) | 2010-10-21 | 2012-05-01 | Oncotherapy Science Inc | WDHD1 peptides and vaccines including the same |
| EP2630237A4 (en) | 2010-10-21 | 2014-04-09 | Oncotherapy Science Inc | C18ORF54 PEPTIDES AND VACCINES CONTAINING THEM |
| CN103339253B (zh) | 2010-12-02 | 2015-09-09 | 肿瘤疗法科学股份有限公司 | Tomm34肽及包含它们的疫苗 |
-
2013
- 2013-09-09 US US14/400,169 patent/US10092634B2/en active Active
- 2013-09-09 ES ES13837757T patent/ES2784862T3/es active Active
- 2013-09-09 SG SG11201501761SA patent/SG11201501761SA/en unknown
- 2013-09-09 AU AU2013317194A patent/AU2013317194B2/en not_active Ceased
- 2013-09-09 JP JP2015530559A patent/JP6283861B2/ja active Active
- 2013-09-09 EP EP13837757.7A patent/EP2895600B1/en active Active
- 2013-09-09 PL PL13837757T patent/PL2895600T3/pl unknown
- 2013-09-09 CN CN201380047407.3A patent/CN104619833B/zh not_active Expired - Fee Related
- 2013-09-09 SG SG10201701866QA patent/SG10201701866QA/en unknown
- 2013-09-09 RU RU2015113436A patent/RU2663350C2/ru active
- 2013-09-09 CA CA2873155A patent/CA2873155C/en active Active
- 2013-09-09 CN CN201711214045.9A patent/CN107881158B/zh not_active Expired - Fee Related
- 2013-09-09 MX MX2015003017A patent/MX362912B/es active IP Right Grant
- 2013-09-09 BR BR112015004349-6A patent/BR112015004349B1/pt not_active IP Right Cessation
- 2013-09-09 DK DK13837757.7T patent/DK2895600T3/da active
- 2013-09-09 KR KR1020147031506A patent/KR102110873B1/ko not_active Expired - Fee Related
- 2013-09-09 WO PCT/JP2013/005321 patent/WO2014041784A1/en not_active Ceased
- 2013-09-10 TW TW102132531A patent/TWI632162B/zh not_active IP Right Cessation
-
2015
- 2015-01-13 IL IL236690A patent/IL236690B/en active IP Right Grant
-
2018
- 2018-08-31 US US16/120,102 patent/US11266729B2/en active Active